尿激酶和瑞替普酶治疗急性心肌梗死溶栓效果的比较分析

Comparative analysis of fibrinolytic therapy effect of urokinase and reteplase at enzyme in the treatment of acute myocardial infarction

目的分析尿激酶和瑞替普酶对急性心肌梗死(AMI)溶栓治疗的效果。方法回顾性分析我院2011年3月～2013年4月期间收治的78例急性心肌梗死患者的临床资料,将其分为对照组与治疗组,对照组采用尿激酶治疗,治疗组采用瑞替普酶治疗,比较分析两组患者的血管再通率、死亡率以及并发症等。结果对照组和治疗组患者的血管再通率分别为53.8%、94.9%;死亡率分别为7.7%、0%;出血并发症率分别为30.8%、17.9%,两组比较,治疗组血管再通时间早、再通比例高,差异有统计学意义(P<0.05)。治疗组患者在溶栓后60 min的血管再通率为64.1%、溶栓后90 min的血管再通率为94.9%、溶栓后120 min的血管再通率为97.4%,与对照组比较差异明显,差异有统计学意义(P<0.05)。结论采用瑞替普酶治疗急性心肌梗死冠脉的再通时间早、冠脉再通率高,且药物维持时间长,患者不良反应较少,是临床一种高效、安全的溶栓药物,值得推广应用。

Objective To study and analyze the fibrinolytic therapy effect of urokinase and reteplase in the treatment of acute myocardial infarction （AMI）. Methods The clinical data of 78 cases of patients with acute myocardial infarction （AMI） who had been treated in our hospital from March 2011 to April 2013 were retrospectively analyzed, they were di vided into control group and treatment group on the average, the control group were given urokinase, and the treatment group were given reteplase treatment, then the blood vessels in the pass rate, mortality and complications, and so on of the two groups of patients were comparatively analyzed. Results The vascular rate of the control group and treatment group of patients were 53.8%, 94.9% respectively; And the mortality rates were 7.7%, 0%; the bleeding complications rate were 30.8%, 17.9% respectively, the recanalization time of the treatment group was early, the recanalization rate was higher than those of the control group, the differences of the two groups were statistically significant （P〈0.05）. The vascular rate of thrombolysis after 60 mins of the treatment group patients was 64.1%, the blood vessels of thrombolysis after 90 mins was 94.9%, and the blood vessel of thrombolysis after 120 mins was 97.4%, the differences of the treat ment group and control group were significant（P〈0.05）. Conclusion Reteplase has earlier coronary artery recanalization time, higher coronary artery recanalization rate, longer drug maintenance time and less adverse reaction in the treatment of acute myocardial infarction, it is a kind of efficient, safe clinical thrombolytic drugs, so is worthy of popularization and application.